Day One Biopharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

Day One Biopharmaceuticals does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-12.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-12.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth

Jul 12

Day One Biopharmaceuticals: Still Uncertainty After FDA Approval

Jul 07

Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair

Apr 24

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Mar 18

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Feb 01

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Dec 04

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

Jun 19

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation

Nov 22

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead

Sep 04

Day One Biopharmaceuticals GAAP EPS of -$0.60

Aug 04

Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price

Jun 18

Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case

Jun 15

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

Apr 29

An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued

Jan 14

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Dec 10

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Aug 27

Day One Biopharma draws bullish calls as quiet period ends

Jun 21

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if DAWN's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if DAWN's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

Day One Biopharmaceuticals Piyasaya Karşı Temettü Getirisi

DAWN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (DAWN)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (DAWN) (3 yıla kadar)	0%

Önemli Temettü: Unable to evaluate DAWN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate DAWN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate DAWN's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as DAWN has not reported any payouts.

Day One Biopharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Co-Founder and Head of R&D notifies of intention to sell stock

Day One Biopharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 30, 2024

New minor risk - Shareholder dilution

Day One Biopharmaceuticals, Inc. announced that it expects to receive $174.999754 million in funding

Consensus revenue estimates increase by 43%

Day One Biopharmaceuticals, Inc. announced that it expects to receive $40 million in funding from Ipsen S.A.

Co-Founder and Head of R&D notifies of intention to sell stock

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth

Day One Biopharmaceuticals: Still Uncertainty After FDA Approval

Co-Founder and Head of R&D notifies of intention to sell stock

Consensus revenue estimates increase by 27%, EPS downgraded

CEO, President & Director notifies of intention to sell stock

Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair

Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma

Day One Biopharmaceuticals, Inc., Annual General Meeting, May 23, 2024

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Consensus revenue estimates fall by 19%

Co-Founder and Head of R&D notifies of intention to sell stock

Day One Biopharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

High number of new directors

Price target decreased by 10% to US$36.88

Day One Biopharmaceuticals, Inc. Announces Board Appointments

Forecast to breakeven in 2026

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Price target increased by 7.6% to US$41.14

New minor risk - Profitability

Day One Biopharmaceuticals, Inc. Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling Nda Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

Consensus revenue estimates fall by 88%

Day One Biopharmaceuticals Announces New FireFLY-1 Data for Tovorafenib (Day101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Price target decreased by 7.5% to US$40.00

Consensus revenue estimates decrease by 11%

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Co-Founder & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$59k worth of stock

COO, CFO & Secretary notifies of intention to sell stock

Co-Founder & Chief Medical Officer notifies of intention to sell stock

Price target increased to US$42.86

Day One Biopharmaceuticals, Inc. Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (Day101) in Recurrent or Progressive Pediatric Low-Grade Glioma

Price target increased to US$38.33

Co-Founder & Director notifies of intention to sell stock

Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation

High number of new and inexperienced directors

CEO, President & Director notifies of intention to sell stock

Day One Biopharmaceuticals Appoints Garry Nicholson as Chairman of the Board of Directors

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead

CEO, President & Director exercised options and sold US$97k worth of stock

Day One Biopharmaceuticals GAAP EPS of -$0.60

CEO, President & Director notifies of intention to sell stock

Day One Biopharmaceuticals, Inc.(NasdaqGS:DAWN) dropped from Russell 2000 Growth Index

Price target increased to US$35.33

Co-Founder & Chief Medical Officer notifies of intention to sell stock

Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price

Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case

Day One Biopharmaceuticals Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Day One Biopharmaceuticals, Inc. Announces First Patients Dosed in Phase 1B/2 Combination Study with Tovorafenib (Day101) and Pimasertib in Raf-Altered Solid Tumors

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

High number of new and inexperienced directors

An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued

High number of new and inexperienced directors

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Co-Founder & Chief Medical Officer notifies of intention to sell stock

Day One Biopharmaceuticals Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Day One Biopharma draws bullish calls as quiet period ends

Day One Biopharmaceuticals, Inc. has completed an IPO in the amount of $160 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin